MedTrace Logo

Study of Nasonex® in Improving Sleep Disturbances Related to Perennial Allergic Rhinitis (Study P04909)(TERMINATED)

NCT00491374 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2009-01-06

Study results available
· View outcomes & findings →

Summary

This study will hope to show that the treatment of the patient's perennial allergic rhinitis (PAR) using Nasonex® (mometasone furoate nasal spray) will result in improvement of the nasal symptoms of PAR and of nighttime sleep-disordered breathing, thereby resulting in improved sleep quality, less daytime sleepiness, improved daytime functioning, and improved quality of life.

Conditions

  • Perennial Allergic Rhinitis

Interventions

DRUG

Mometasone Furoate Nasal Spray

Nasonex Nasal Spray 50 mcg/spray, 200 mcg (4 sprays) once daily every morning for 28 days.

DRUG

Placebo

Placebo Nasal Spray 4 sprays once daily every morning for 28 days.

Sponsors & Collaborators

  • Schering-Plough

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Completion
2007-10-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00491374 on ClinicalTrials.gov